GLP1R and ovarian carcinoma: In that report by Dai et al., the authors pooled various GLP-1 receptor agonists with different pharmacology properties into one group and found that GLP-1 receptor agonists were associated with a reduced risk of endometrial cancer and ovarian cancer [141].